Q-omics provides the consensus-scored ZNF460 profile across patient tissues and cancer cell-line models. ZNF460 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, ZNF460 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, ZNF460 RNA expression shows 20,700 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, KIRC, and ACC as cancer lineages where ZNF460 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF460 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF460 survival associations across molecular data types. ZNF460 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF460 RNA expression–survival associations across cancer types. High ZNF460 expression shows unfavorable associations in ACC and MESO, but favorable associations in SCLC, UCS, KIRC and UCEC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for ZNF460 RNA expression.
This table summarizes ZNF460 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF460. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF460 shows lower tumor expression in KIRC and THCA and higher tumor expression in HNSC, COAD, CHOL and STAD. The KIRC box plot shows higher ZNF460 RNA expression in normal versus tumor tissue (log2 FC = −0.584, t-test p < 0.001).
This table shows molecular features associated with ZNF460 in patient tissues and cancer cell lines. In patient samples, ZNF460 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF460 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
